Advances in Tuberculosis Diagnosis and Treatment before and after COVID-19
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Diagnostic Microbiology and Infectious Disease".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 1337
Special Issue Editor
Interests: prevention and vaccination; immunological features; infectious diseases; global health; tuberculosis; COVID-19; autoimmunity; ASIA-syndrome
Special Issue Information
Dear Colleagues,
At the beginning of the 21st century, tuberculosis remained a pressing issue that received attention at various levels. Being one of the leading causes of death worldwide, it is still a marker of the country's social and economic well-being.
The pandemic of the new coronavirus infection (COVID-19) introduced significant adjustments to TB care programs around the globe, which has affected the detection of new cases of TB in all countries of the world and the mortality due to the infection. COVID-19 had a significant impact not only on the diagnosis of TB infection but the change in the immune status of TB patients.
However, questions relating to TB infection diagnosis can affect an increase in the mortality rate in TB patients and it can affect an increase in tuberculosis in the future. The specificity of the features of the immune response in patients with COVID-19 showed the presence of similar characteristics of the cellular component of the immune response which can lead to a severe course of tuberculosis.
Currently, one of the main tasks in the fight against the global problem of tuberculosis is the issue of the availability of anti-tuberculosis treatment for patients. TB patients with MDR and XDR TB are the most difficult category of patients with comorbidity in 74% of cases, including 6% of cases occurring with an HIV infection. In the conditions of the continued growth of multiple- and extensively drug-resistant tuberculosis, the use of the new highly effective anti-tuberculosis drugs in this patient category is of great relevance.
Prof. Dr. Anna Starshinova
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tuberculosis, pathogenesis
- coronavirus infection, COVID-19, SARS-CoV-2, the immune response cells, treatment efficacy
- multidrug resistance
- extensive drug resistance
- mycobacterium tuberculosis, autoimmunity
